BioSpace News Archive

Policy

FDA Summit on Gene Therapy Risks Proves Timely

The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.

September 7, 2021
·
4 min read
·
Heather McKenzie
Drug Development

FDA Slaps a Hold on BioMarin’s PKU Gene Therapy

Gene therapy clinical trials have been paused due to safety concerns, including the most recent one by BioMarin Pharmaceutical.

September 7, 2021
·
3 min read
·
Mark Terry
Business

Collaboration Sparks Hope for Huntington’s Disease Cure

The collaboration between Spark and NeuExcell increased the hope for Huntington’s disease cure in near future. This is going to be a great relief for all the patients.

September 7, 2021
·
2 min read
·
Vanessa Doctor, RN
Biotech Bay

Introducing Cas7-11—A New Addition to the CRISPR Toolkit

The new bacterial enzyme has the ability to cut and modify RNA with the exquisite precision that has only been possible so far for DNA editing.

September 7, 2021
·
4 min read
·
Heather McKenzie
Policy

Delta Remains Largest Concern as COVID-19 Cases Increased 316% in the Last Year

Concerns about Mu and Lambda are growing, but data suggests that Delta is still the biggest problem. The U.S. is also struggling with infections this year. Here’s the latest news.

September 7, 2021
·
3 min read
·
Mark Terry
Business

Exelixis Mourns Loss of Two Veteran Execs

Exelixis is mourning the loss of two veteran executives—Dr. Gisela M. Schwab, president, Product Development and Medical Affairs and CMO, and Jon Berndt, senior VP of Sales.

September 7, 2021
·
2 min read
·
Kate Goodwin
Business

Collab Worth Up to $3 Billion for Off-the-Shelf T-Cell Cancer Therapies

Adaptimmune will be responsible for developing clinical T-cell candidates for the two companies through its induced pluripotent stem cell (iPSC) derived allogeneic platform.

September 7, 2021
·
2 min read
·
Alex Keown
Business

Ginkgo’s Momentum Continues with Latest String of Collaboration Announcements

Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.

September 7, 2021
·
2 min read
·
Ellen Bombela
Business

Fountain’s William Greene is Striving to Extend Human Health Span

Last spring he joined Fountain Therapeutics as CEO, a company that merges artificial intelligence (AI) with machine learning (ML) to develop therapeutics for degenerative diseases.

September 7, 2021
·
5 min read
·
Gail Dutton
Drug Development

New Phase III Data Reaffirms Tezepelumab’s Potential for Severe Asthma

The analysis showed tezepelumab achieved an 86% reduction in the annualized asthma exacerbation rate with patients having nasal polyps, and 52% in patients not having nasal polyps.

September 7, 2021
·
4 min read
·
BioSpace Editorial Staff